Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial
about
A review of national guidelines for management of COPD in EuropeMuscarinic antagonists in early stage clinical development for the treatment of asthma.Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD.Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.Long-acting muscarinic antagonists.Inhaled treatment for chronic obstructive pulmonary disease: what's new and how does it fit?Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapySafety of inhaled long-acting anti-muscarinic agents in COPD.Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease.Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.Triple Therapy in COPD: What We Know and What We Don't.Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD.Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.Effect of background long-acting beta-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPDPreventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β-Agonist Therapy: An Integrated Post Hoc AnalysisA randomized trial of symptom-based management in Japanese patients with COPD
P2860
Q28072014-F14722F3-95CD-4B86-A3D8-51DB1B8EC9ADQ30396144-C1DAEA40-232D-4D95-B841-EDD287E9636EQ31165976-DA79009A-5E94-406A-A880-A74E6C16DB11Q34550471-E25184AD-D2DF-49B6-B17F-A416FE45A999Q36704580-45881531-49F8-47E9-B4D4-53F18A067039Q38537326-CAA2142F-65C0-43EB-B46F-FE8037A682E0Q38630770-999E433C-3658-4301-A5C4-1D1ED3A74A09Q38660895-2BCF7837-C4AD-408A-9130-5A0618D5FE5EQ39003291-0D68A5BB-C36A-494A-BD5A-20264F2EE90EQ39232425-75226968-2A13-4537-ABD0-C0D0106EB88DQ40598255-DF2920FB-875C-4821-B054-EF61C6BDD682Q41018618-CA302025-DCFF-4E79-985B-0240C0F7C2E6Q41282858-D6B39396-A2D3-4CD8-ABBE-4224930940FBQ42920605-1EC23C96-365F-4579-8301-0A11C8AA0CFEQ47984024-9B3BC10D-BDE9-48CC-8815-0AC59779802DQ48335044-C5DC73AD-1D4C-4D70-B4ED-AD50848F6A97Q55021618-AAFA60BC-90A5-4F77-85F3-B3081BEE3153Q55120067-F611DA58-27AD-4D03-8E7C-B5B91BADFF91Q55387524-A8B47B23-11F4-4B1A-8712-8EBACF32E649Q57073287-CD196841-CE9A-4841-995A-442B5B8333BCQ58760591-67DA8708-ED41-4F84-914C-10C212D4E4D8Q58785953-C8E20DB7-3445-4B15-B062-9A1C96E32F04
P2860
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Glycopyrronium once-daily sign ...... a randomised controlled trial
@ast
Glycopyrronium once-daily sign ...... a randomised controlled trial
@en
type
label
Glycopyrronium once-daily sign ...... a randomised controlled trial
@ast
Glycopyrronium once-daily sign ...... a randomised controlled trial
@en
prefLabel
Glycopyrronium once-daily sign ...... a randomised controlled trial
@ast
Glycopyrronium once-daily sign ...... a randomised controlled trial
@en
P2093
P2860
P1433
P1476
Glycopyrronium once-daily sign ...... a randomised controlled trial
@en
P2093
Catherina L Chang
Christina Frenzel
Glisten Study Group
Nicol Kurstjens
Peter A Frith
Peter Bremner
Philip J Thompson
Rajeev Ratnavadivel
P2860
P304
P356
10.1136/THORAXJNL-2014-206670
P407
P577
2015-04-03T00:00:00Z